en · de · es · fr · pt
cardarine-notes.peptides6155.com › Topic › Background And Research Context — Background and Details

Background And Research Context — Background and Details

By Editorial Desk · published 2025-08-16 · last reviewed 2025-09-21 · Topic

This is a working overview of Investigational drug, written for readers who want more than a one-paragraph summary but less than a textbook.

Reviewed 2025-09-21. Anything still debated is marked as such rather than presented as settled.

Background and Research Context

Cardarine is a common name for GW501516, a synthetic compound developed in the 1990s through research collaborations involving GlaxoSmithKline. It belongs to a class of molecules known as peroxisome proliferator-activated receptor delta agonists. Early studies explored its effects on lipid metabolism and energy expenditure in animal models. The compound was never approved as a human medicine, and clinical development was discontinued. In the years since, it has appeared in fitness and bodybuilding communities as a performance-enhancing substance. Regulatory agencies classify it as an unapproved drug.

PPARδ is a nuclear receptor that regulates gene expression related to fatty acid oxidation, glucose homeostasis, and mitochondrial function. GW501516 binds to this receptor with high affinity and activates downstream signaling in skeletal muscle and other tissues. Animal studies reported increased endurance and altered fuel preference, but human data remain limited and inconsistent. The precise relationship between receptor activation and observed physiological changes is still an area of active investigation. Researchers have also examined whether the compound affects inflammation or cell proliferation. No approved therapeutic indication exists for cardarine.

Mechanism and Research Context

Laboratory studies have examined GW501516 in cell cultures and rodents for conditions such as dyslipidemia, insulin resistance, and obesity. Some trials in humans were initiated, but development was discontinued after preclinical findings raised concerns about cancer in certain models. Those findings do not prove that the compound causes cancer in people, but they contributed to regulatory caution. Later reviews often describe the evidence as preliminary and insufficient for assessing long-term safety.

In the fitness and bodybuilding literature, cardarine is frequently discussed as an endurance agent or fat-loss compound, although such claims are not supported by robust clinical evidence. Online descriptions often mix animal data, user anecdotes, and marketing language. Researchers who study PPARδ agonists distinguish between receptor activation in controlled experiments and unsupervised use of unverified products. The latter introduces unknown purity, dose, and interactions, making reported experiences difficult to interpret scientifically.

GW501516 acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in transcription of genes related to lipid handling and energy use. Activation of PPARδ can shift skeletal muscle toward greater fatty acid oxidation in animal models, which is one reason it drew interest for metabolic disease and exercise research. The exact downstream effects depend on tissue, species, dose, and duration. Human data are sparse, so many proposed benefits remain hypotheses rather than established clinical outcomes.

Cardarine at a glance

PropertyValueNotes
CAS Registry Number317318-70-0Unique identifier for the compound.
Chemical classPPARδ agonistSynthetic ligand for peroxisome proliferator-activated receptor delta.
AppearanceWhite to off-white solidTypical form of research-grade material.
SolubilitySoluble in DMSO and ethanolPoorly soluble in water.
Typical storage-20°CRecommended for long-term storage of stock solutions.

Background and Regulatory History

Regulatory bodies treat GW501516 as a prohibited substance in competitive sport. The World Anti-Doping Agency added it to the prohibited list, and it falls under classes covering metabolic modulators and hormone-related agents. It is not approved by drug regulators for human use, and it is not a lawful dietary supplement. Products sold under the cardarine name may contain unlisted ingredients or different compounds. Because no approved product exists, quality and identity are not guaranteed by pharmaceutical manufacturing standards.

Cardarine is a common name for the investigational chemical GW501516, also written GW-1516. It was developed as a peroxisome proliferator-activated receptor delta agonist for metabolic conditions such as dyslipidemia. Early research focused on lipid handling and energy use in skeletal muscle and other tissues. The compound was never approved as a medicine. In public discussion, it is often grouped with performance-enhancing substances, although its receptor target differs from that of anabolic steroids or selective androgen receptor modulators. Regulatory and health authorities have issued warnings about its use.

GW501516 acts on PPARδ, a nuclear receptor that helps regulate fatty acid oxidation and energy homeostasis. In animal studies, activation of this receptor was associated with increased endurance and changes in lipid metabolism. Human trials examined effects on blood lipids and other metabolic markers, but the compound did not advance to approval. Rodent studies later reported tumors in multiple tissues at doses used in those experiments. Whether those findings translate to human risk remains uncertain, and the clinical relevance of the animal data is still debated.

Related pages on this site

Preclinical Findings and Safety Signals

Safety concerns emerged from long-term animal studies. In rodents given the compound for extended periods, researchers found an increased incidence of certain cancers, including liver and bladder tumors. These findings contributed to the discontinuation of clinical development. Whether similar risks apply to short-term or low-level exposure in humans is not established, and controlled human safety data are limited. The relevance of high-dose rodent carcinogenicity findings to human use remains a subject of debate.

Human trials of GW501516 were small and short in duration. They examined lipid levels, glucose handling, and other metabolic markers, but the programs were halted after the animal cancer findings. No approved therapeutic product exists, and published human data are insufficient for establishing long-term safety. Reports of use for athletic performance come mainly from non-clinical settings and cannot be verified through controlled trials. Independent testing of products sold as cardarine has found inconsistent purity and labeling.

Mechanism and Laboratory Detection

GW501516 binds and activates PPARδ, a nuclear receptor that influences transcription of genes involved in fatty acid oxidation and energy use. Activation shifts some metabolic pathways in preclinical models, which is why the compound has been studied for lipid disorders and exercise-related endpoints. The exact downstream effects in humans are incompletely mapped. PPARδ is expressed in many tissues, including skeletal muscle, liver, and adipose tissue, so broad activation may have varied consequences. Researchers continue to examine how selective or partial activation might alter the balance between benefits and risks.

Published human data are sparse and mostly come from early-phase trials. Those studies examined short-term changes in lipids, glucose, and exercise capacity, but they were not large enough to establish efficacy or long-term safety. Some animal experiments reported increased running endurance, yet such findings do not prove a performance benefit in people. Anti-doping laboratories detect GW501516 and its metabolites in urine or blood using liquid chromatography-tandem mass spectrometry. Detection windows depend on dose, sample type, and individual metabolism. The method is sensitive enough to identify trace residues in tested samples.

Cardarine Identity and Mechanism

Cardarine is the common name for GW501516, a synthetic compound studied as a peroxisome proliferator-activated receptor delta agonist. Researchers developed it to explore treatments for lipid disorders and metabolic conditions. It is not an approved medicine in any country. Early clinical work examined changes in HDL cholesterol and triglycerides, but development was discontinued after animal studies raised concerns about cancer. The compound remains available as a research chemical and appears in discussions of performance enhancement.

At the molecular level, GW501516 binds and activates PPARδ, a nuclear receptor that regulates transcription. Activation shifts expression of genes involved in fatty acid oxidation, energy expenditure, and lipid transport in skeletal muscle and liver. Animal studies report increased endurance and altered lipid profiles after exposure. Human data are limited to small trials and do not establish long-term safety or efficacy. PPARδ also has roles in cell proliferation, so the relationship between activation and cancer risk remains an open question.

Published literature on cardarine includes in vitro assays, rodent experiments, and a small number of human studies. Reports describe effects on exercise capacity and lipid metabolism in animals, while human evidence is sparse. Many online descriptions present the compound as a proven endurance aid, a claim not supported by regulatory approval or large clinical trials. Analytical studies focus on identifying the parent compound and its metabolites in biological samples. Important uncertainties include species differences, dose-response relationships, and the relevance of rodent tumor findings to humans.

Background from the literature

NETA is used as a hormonal contraceptive in combination with estrogen, in the treatment of gynecological disorders such as abnormal uterine bleeding, and as a component of menopausal hormone therapy for the treatment of menopausal symptoms. NETA is available in the form of tablets for use by mouth both alone and in combination with estrogens including estradiol, estradiol valerate, and ethinylestradiol. Transdermal patches providing a combination of 50 μg/day estradiol and 0.14 or 0.25 mg/day NETA are available under the brand names CombiPatch and Estalis. NETA was previously available for use by intramuscular injection in the form of ampoules containing 20 mg NETA, 5 mg estradiol benzoate, 8 mg estradiol valerate, and 180 mg testosterone enanthate in oil solution under the brand name Ablacton to suppress lactation in postpartum women. Side effects of NETA include menstrual irregularities, headaches, nausea, breast tenderness, mood changes, acne, increased hair growth, and others.

== Occurrence and production == Technetium occurs naturally in the Earth's crust in minute concentrations of about 0.003 parts per trillion. Technetium is so rare because the half-lives of 97Tc and 98Tc are only 4.2 million years. More than a thousand of such periods have passed since the formation of the Earth, so the probability of survival of even one atom of primordial technetium is effectively zero. However, small amounts exist as spontaneous fission products in uranium ores. A kilogram of uranium contains an estimated 1 nanogram (10−9 g), equivalent to ten trillion atoms, of technetium. Some red giant stars with the spectral types S, M, and N display a spectral absorption line indicating the presence of technetium. These red giants are known informally as technetium stars.

The London and Home Counties Traffic Advisory Committee was established in 1924 to advise the Minister of Transport on issues concerning traffic and transport in the London Traffic Area. It was abolished in 1965. The purpose of the committee, as stated in the Act was "giving advice and assistance in manner provided by this Act to the Minister of Transport... in connection with the exercise and performance of his powers and duties in relation to traffic within the... London Traffic Area..."

It also has the largest Brazilian community in the UK; one of the largest Indian communities; a significant Afro-Caribbean community; and more recent Romanian, Polish and Somali communities. The 2021 census showed that 1.3% of adults in Brent identified as transgender, derived from the Census question, "Is the gender you identify with the same as your sex registered at birth?". This gave Brent the second highest proportion of transgender adults after the Borough of Newham (at 1.5%). The overall proportion in England and Wales was 0.5% with Brighton, an area well known for its LGBT communities, 1%. However, Prof Michael Biggs of Oxford University showed there was a correlation between the proportion of transgender people in these areas and the proportion for whom English was not their first language (34% in Brent and 35% in Newham, compared to 9% nationally), suggesting the question was not fully understood by some. Prof Biggs described the figures as "irredeemably flawed". In September 2024, Mary Gregory, a deputy director at the ONS said some people may have misunderstood the question, saying there was "potential bias" in how the question was answered "by those who responded that they had lower levels of English proficiency, some of whom may have mistakenly given an answer suggesting they were trans". As a result, the ONS downgraded the data from "accredited official statistics" to "official statistics in development" to reflect the possible flaws.

Sources: en.wikipedia.org

Reference notes

Casein ( KAY-seen; from Latin caseus, 'cheese') is a family of related phosphoproteins (αS1, aS2, β, κ) that are commonly found in mammalian milk, comprising about 80% of the proteins in cow's milk and between 20% and 60% of the proteins in human milk. Sheep and cow milk have a higher casein content than other types of milk with human milk having a particularly low casein content. Casein does not appear to be essential in mammals. For example, the β-casein gene can be deleted in mice. The resulting mice are healthy and fertile, but the growth of their pups is reduced. Similarly, mice lacking the κ-casein gene are healthy, but they did not suckle their pups and failed to lactate, hence the gene is required for reproductive success.

The heat-resistant enzymes that are a key component in polymerase chain reaction were discovered in the 1960s as a product of a microbial life form that lived in the superheated waters of Yellowstone's Mushroom Spring. A 1971 paper in the Journal of Molecular Biology by Kjell Kleppe and co-workers in the laboratory of H. Gobind Khorana first described a method of using an enzymatic assay to replicate a short DNA template with primers in vitro. However, this early manifestation of the basic PCR principle did not receive much attention at the time and the invention of the polymerase chain reaction in 1983 is generally credited to Kary Mullis.

Skates, rays, small sharks of the genus Mustelus, mullets and bonito were among the fish caught off the Peruvian coast. Other sea creatures like seabirds, penguins, sea lions and dolphins were eaten, as were various crustaceans and chitons, limpets, mussels, chanque (an abalone-like animal). Like other American peoples, the Inca ate animals that were often considered vermin by many Europeans, such as frogs, caterpillars, beetles, and ants. Mayfly larvae were eaten raw or toasted and ground to make loaves that could then be stored. The Inca's intricate food preservation methods and storage system allowed for there to be enough food in times of need (when crops failed, during times of war) or in times of success (when celebrating and rewarding everyone's hard work).

== Awards == Royal Society of Western Australia, University Medal for outstanding student in natural and earth sciences (2003) Society of Environmental Toxicology and Chemistry, Best Platform Presentation by a student (2008) FNR ATTRACT Fellowship for the development of new methods to identify unknown chemicals (2018) The Analytical Scientist, Top 40 under 40 Power List (2018) The Analytical Scientist Power List, "Planet Protectors" field (2024)

The player must explore others houses and buildings around the map to find food and water to avoid starving and dehydrating, which will end the game (if on permadeath mode; otherwise, they will respawn back at the last hatch they visited.) The Night Watch mode focuses on the game's combat features and instead of being a downer, the player plays as a Bobby named John Constable (or "Constable Constable" for short). The player spawns on a randomly generated island in the Village of Hamlyn, with no bridges leading off of the island. The mode is round-based, and to advance the rounds, the player must eliminate all enemies that spawn in until the rounds timer ends, in which the player can use a Bobby Popper to end the round. The player earns money (pounds) by eliminating enemies, consisting of Downers, "Headboys", Plaguies, and Wastrels. Witches can spawn, serving as mini-bosses and dealing the most damage out of any enemy, but also give major rewards when defeated. As well as spending their money on vending machines to gain better gear and items, players must spend their money on Joy, which they need to do regularly as their Joy Meter goes down. If the player character run out of Joy, the game ends. Joy starts at £20, but the price goes up every round. The player always takes Blackberry Flavour of Joy, a rarer version of the drug exclusively made for the Bobbies. As the player defeats enemies, their Rage Meter grows, with one slot of it being filled per elimination.

Sources: en.wikipedia.org

Frequently asked questions

What is cardarine?

Cardarine is a common name for GW501516, a synthetic PPARδ agonist developed for research. It has not been approved as a medication in any country. It is classified as an unapproved drug and a prohibited substance in sport.

Is cardarine a steroid?

No. Cardarine is not an anabolic steroid; it belongs to a different chemical class that targets PPARδ. Steroids act primarily through androgen receptors, while cardarine acts through a nuclear receptor involved in metabolism.

What did animal studies find?

Some rodent studies reported increased endurance and changes in fat metabolism after cardarine exposure. Long-term studies in animals also raised concerns about cancer in certain tissues. Human trial data are limited, so these findings cannot be directly translated to people.

How does cardarine work in the body?

It binds and activates PPARδ, a nuclear receptor that influences gene expression related to fatty acid metabolism and energy balance. This mechanism has been studied mainly in animals and cell models, not established as a safe human therapy.

Network